Barrington Research Reiterates Buy Rating on LFCR
Barrington Research maintains its buy rating on LFCR with a price target of $6.50, a 17.33% upside from the current price.
Key Points
- Barrington Research reiterated its buy rating on LFCR, setting a price target of $6.50 on June 16, 2026.
- Barrington Research's $6.50 price target implies 17.33% upside from Lifecore Biomedical, Inc.'s ($LFCR) current $5.54 share price.
- LFCR shares recently traded at $5.49, with insider buying activity recorded on June 4, 2026.
- Peers like BlackRock and Greenhaven Road adjusted their LFCR positions, while Vanguard initiated a new stake.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barrington Research has reiterated its buy rating on LFCR, setting a new price target of $6.50. This update came on June 16, 2026, as the stock traded around $5.49.
Other Institutional Activity in LFCR
Wynnefield Capital Inc held steady with 4,703,216 shares valued at about $17.5 million. Legion Partners Asset Management LLC also maintained its position with 4,461,823 shares worth roughly $16.6 million. Meanwhile, Greenhaven Road Investment Management, L.P. trimmed its holdings by 145,000 shares, ending with 3,537,573 shares valued at approximately $13.2 million. BlackRock, Inc. reduced its stake by 29,779 shares, bringing its total to 1,877,305 shares, valued at around $6.98 million. In contrast, Vanguard Capital Management LLC initiated a new position with 1,290,136 shares valued at about $4.8 million.
Lifecore Biomedical, Inc. Stock Up 22.0%
LFCR shares are currently trading near $5.49. The stock has seen various institutional movements, reflecting different strategies among investors.
Insider Buying and Selling at Lifecore Biomedical, Inc.
On June 4, 2026, several insiders, including Christopher Kiper, Matthew Korenberg, Humberto Calheiros Antunes, Katrina Houde Lovas, Nelson Obus, and Paul Harold Johnson, each bought 25,907 shares. These transactions were not part of any pre-planned trading scheme.
Analysts Set New Price Targets
On June 16, 2026, Barrington Research maintained its buy rating on LFCR, setting a price target of $6.50. Previously, on April 29, 2026, the firm had set a $6.00 target, and in March, it had a target of $5.50. Stephens & Co. reiterated a hold rating with a $6.00 target back in January 2025, while Craig-Hallum maintained a buy rating with a $10.00 target in November 2024.
Bottom Line
Barrington Research's reiterated buy rating and updated price target suggest confidence in LFCR's potential. With insider buying and varied institutional activity, LFCR remains a stock to watch. Remember, these analyst ratings are backward-looking and may not reflect current market conditions.
Get Lifecore Biomedical, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LFCR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.